To include your compound in the COVID-19 Resource Center, submit it here.

For:
ads
Product Development
Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the ...

The critical path to COVID-19 therapies

The path to safe, effective COVID-19 therapies is crowded and poorly marked. There is an urgent need to fast-track a manageable number of therapies, illuminate every step along the ...

The pivotal role of real-world data in a pandemic

Real-world data is taking on a critical role in the age of COVID-19 drug development, where hasty authorizations are being made on limited datasets and natural history data is ...

Preparing for COVID-19 vaccine success

The European Commission and international organizations are working to create a purchasing pool for global allocation of COVID-19 vaccines, according to Nicole Lurie, strategic ...

Sorting out COVID-19 consortia

Several consortia have brought together biopharmas, government agencies, non-profits, academics and VCs to accelerate the development of COVID-19 countermeasures. These groups have ...

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data
Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after ...

Politics, Policy & Law
Trump abandons WHO, strikes out at China with isolationist policies

After months of blaming China and the World Health Organization for the scope and severity of the COVID-19 pandemic, President Donald Trump lashed out at both again Friday with a ...

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS ...

WHO launches COVID-19 patent pool into headwinds

The World Health Organization launched its COVID-19 patent pool Friday facing significant obstacles that include a lack of support from China, the U.K. and the U.S., as well as ...

Proposed changes to CFIUS rules would ensnare more Chinese-backed U.S. biotechs

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could ...

Finance
Ovarian cancer data help Mersana raise $152M to top off an $8B month of follow-ons

Catalyzed by interim data unveiled Wednesday from a Phase I trial of its lead product, Mersana raised $152 million late Thursday to advance its clinical and preclinical ...

Daily Chart: May follow-on frenzy

May ended with a whopping $9 billion in follow-on capital raised for life

Read the full 138 word ...

GV’s 2020 viewpoint

GV thinks its funding structure will allow it to weather the year’s financial storms and keep working to plug gaps in the healthcare system.

The venture arm ...

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond ...

Translation in Brief
Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy
A McMaster University and University of Toronto team revealed in a Cell Stem Cell

Management Tracks
Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Incoming CEO David Loew will arrive as Ipsen tries to recover from setbacks that have hobbled development of palovarotene, one of its two candidates to treat rare disease FOP and ...

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit ...

BioCentury ISSN 1097-7201